Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants (DACUS)

This study has been completed.
Sponsor:
Information provided by:
Azienda Ospedaliera Universitaria Policlinico
ClinicalTrials.gov Identifier:
NCT00438230
First received: February 20, 2007
Last updated: February 21, 2007
Last verified: February 2007
  Purpose

ABSTRACT Background The optimal duration of oral anticoagulant treatment in patients with idiopathic venous thromboembolism is still uncertain . The present study addressed the possible role of the Residual Vein Thrombosis in assessing the need for a prolonged anticoagulation.

Methods Patients with a first episode of symptomatic unprovoked or provoked proximal Vein Thrombosis (VT) were given Oral Anticoagulant Treatment (OAT) for 3 months. Residual Vein Thrombosis (RVT), ultrasonographically-detected, will be then assessed. Patients without RVT did not continue OAT, whereas those with RVT will be randomized to either stop or continue OAT for 9 more months. Patients were followed-up prospectively focusing on the study outcomes: occurrence of recurrent venous thromboembolism and major bleeding over a period of at least 12 months after OAT discontinuation.


Condition Intervention Phase
Deep Vein Thrombosis
Drug: Warfarin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Residual Vein Thrombosis (RVT) Establishes the Optimal Duration of Oral Anticoagulants After a First Episode of Deep Vein Thrombosis of the Lower Limbs

Resource links provided by NLM:


Further study details as provided by Azienda Ospedaliera Universitaria Policlinico:

Primary Outcome Measures:
  • Recurrent Venous Thromboembolism
  • major and minor haemorrhage
  • death

Estimated Enrollment: 250
Study Start Date: November 2003
Estimated Study Completion Date: September 2006
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • First episode of unprovoked and provoked proximal DVT of the lower limbs and treated for 3 month with oral anticoagulants

Exclusion Criteria:

  • Active cancer,
  • Limited life expectancy,
  • Antiphospholipid antibody syndrome, or an other known thrombophilic status (such as antithrombin deficiency),
  • Serious liver disease,
  • Renal insufficiency (serum creatinine > 2 mg/dL).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00438230

Sponsors and Collaborators
Azienda Ospedaliera Universitaria Policlinico
Investigators
Study Chair: Sergio Siragusa, MD University Hospital of Palermo
  More Information

No publications provided by Azienda Ospedaliera Universitaria Policlinico

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00438230     History of Changes
Other Study ID Numbers: 000743
Study First Received: February 20, 2007
Last Updated: February 21, 2007
Health Authority: Italy: National Bioethics Committee

Keywords provided by Azienda Ospedaliera Universitaria Policlinico:
Residual vein thrombosis
Optimal duration
Oral anticoagulants

Additional relevant MeSH terms:
Thrombosis
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 18, 2014